Cargando…
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and envir...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830546/ https://www.ncbi.nlm.nih.gov/pubmed/29446765 http://dx.doi.org/10.1038/ctg.2018.2 |
_version_ | 1783303018488266752 |
---|---|
author | Stern, Emily K Brenner, Darren M |
author_facet | Stern, Emily K Brenner, Darren M |
author_sort | Stern, Emily K |
collection | PubMed |
description | Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification. SYN-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant IBS. Use of these interventions in the management of patients with IBS may function to restore a healthy gut microbiota and ameliorate symptoms of IBS. |
format | Online Article Text |
id | pubmed-5830546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58305462018-03-05 Gut Microbiota-Based Therapies for Irritable Bowel Syndrome Stern, Emily K Brenner, Darren M Clin Transl Gastroenterol Clinical and Systematic Reviews Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification. SYN-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant IBS. Use of these interventions in the management of patients with IBS may function to restore a healthy gut microbiota and ameliorate symptoms of IBS. Nature Publishing Group 2018-02 2018-02-15 /pmc/articles/PMC5830546/ /pubmed/29446765 http://dx.doi.org/10.1038/ctg.2018.2 Text en Copyright © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Clinical and Systematic Reviews Stern, Emily K Brenner, Darren M Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title_full | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title_fullStr | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title_full_unstemmed | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title_short | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
title_sort | gut microbiota-based therapies for irritable bowel syndrome |
topic | Clinical and Systematic Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830546/ https://www.ncbi.nlm.nih.gov/pubmed/29446765 http://dx.doi.org/10.1038/ctg.2018.2 |
work_keys_str_mv | AT sternemilyk gutmicrobiotabasedtherapiesforirritablebowelsyndrome AT brennerdarrenm gutmicrobiotabasedtherapiesforirritablebowelsyndrome |